

CURRICULUM VITAE

David G. Miller, MD

OFFICE ADDRESSES Retina Associates of Cleveland, Inc.
3401 Enterprise Parkway, Suite 300; Cleveland, Ohio 44122
14601 Detroit Avenue, Suite 200; Cleveland, Ohio 44107
15299 East Bagley Road, Suite 200; Cleveland, Ohio 44130
5390 Belmont Avenue; Youngstown, Ohio 44505
1 Park West, Suite 150; Akron, Ohio 44320
3919 East Market Street; Warren, Ohio 44484
9485 Mentor Avenue, Suite 211; Mentor, Ohio 44060
6100 South Broadway Avenue, Suite 200; Lorain, Ohio 44052

TELEPHONE 216-831-5700

EDUCATION

College The Ohio State University
Columbus, Ohio
1985-1989, BS (Chemistry)

Medical School University of Cincinnati
Cincinnati, Ohio
1989-1993, MD

POSTGRADUATE TRAINING

Internship Medicine
University Hospital
Cincinnati, Ohio
1993-1994

Residency Ophthalmology
Indiana University Medical Center
Indianapolis, Indiana
1994-1997
Chief Resident, 1996-1997

Fellowship Vitreo-Retinal Surgery and Disease Fellowship
Massachusetts Eye and Ear Infirmary
Harvard Medical School
Boston, Massachusetts
1997-1998

LICENSURE AND BOARD CERTIFICATION

Licensed to practice medicine in Ohio

Diplomate, American Board of Ophthalmology, 1999

PROFESSIONAL POSITIONS

Retina Associates of Cleveland, 1998-

Practice limited to retinal diseases and surgery

President, 2009-

Associates: Lawrence J. Singerman, MD; Michael A. Novak, MD; Hernando Zegarra, MD; Z. Nicholas Zakov, MD; Scott D. Pendergast, MD; Joseph M. Coney, MD; Jerome P. Schartman, MD.

Cleveland Eye and Laser Surgery Center

Medical Director, 2007-

President of Governing Board, 2007-

Ohio Eye Injury Registry

Chairman, 2002-

ACADEMIC AND TEACHING ACTIVITIES

Chief Teaching Resident, Indiana University Medical Center, Department of Ophthalmology; 1996-1997

Medical student lectures and testing, grand rounds scheduling, guest speakers, interdepartmental education

Medical Biochemistry Recitation Leader, University of Cincinnati; 1990-1991

Biochemical problem-solving guidance for first-year medical students

Research Intern, National Institutes of Health, Bethesda, Maryland; 1989

Biochemical studies concerning ozone oxidation of proteins

PROFESSIONAL SOCIETIES AND COMMITTEES

Cleveland Ophthalmological Society

President, 2004-2005

President-elect, 2003-2004

Vice President, 2002-2003

Treasurer, 2000-2002

Diabetic Retinopathy Clinical Research Network Group

Protocol Development Committee, 2005

Scientific reviewer, *Survey of Ophthalmology*

Scientific reviewer, *Journal of Cataract and Refractive Surgery*

Scientific reviewer, *Retina, The Journal of Retinal and Vitreous Diseases*

HONORS AND AWARDS

Best Doctors in America, 2011

Best Doctors in Cleveland, *Cleveland Magazine*, 2011

Member, Phi Beta Kappa

The Ohio State University

Summa cum laude with Honors in the Liberal Arts

Outstanding Senior in Chemistry Award

Phi Beta Kappa

Ohio Regents Scholar

Ohio State University Distinguished Scholar

President's Award for Excellence in Scholarship

University of Cincinnati College of Medicine

Alpha Omega Alpha Medical Honor Society, junior year inductee

Medical Student Research Award

College of Medicine Merit Award

James R. Nicholl Memorial Scholar

MEMBERSHIPS

Alpha Omega Alpha Medical Honor Society

American Academy of Ophthalmology

American Eye Study Club

American Medical Association

American Society of Vitreoretinal Specialists (formerly the Vitreous Society)

Massachusetts Eye and Ear Infirmary Alumni Association

Ohio State Medical Association

Ohio Ophthalmological Society

Phi Beta Kappa

HOSPITAL AFFILIATIONS

Lakewood Hospital

Cleveland Clinic Foundation

Parma Community Hospital

Hillcrest Hospital

Fairview Hospital

Lake Hospital System
Community Health Partners
EMH Regional Medical Center

RESEARCH ACTIVITIES

NIH-funded Grants

DRCRnet Protocol K. Course of response to focal photocoagulation for diabetic macular edema (Diabetic Retinopathy Clinical Research Network /NIH)

Principal investigator, 2007-2008

DRCRnet Protocol D. Evaluation of vitrectomy for diabetic macular edema (Diabetic Retinopathy Clinical Research Network /NIH)

Principal investigator, 2006-

DRCRnet Protocol I. Intravitreal ranibizumab or triamcinolone acetonide in combination with laser photocoagulation for diabetic macular edema (Diabetic Retinopathy Clinical Research Network /NIH)

Principal investigator, 2007-

DRCRnet Protocol N. An evaluation of intravitreal ranibizumab for vitreous hemorrhage due to proliferative diabetic retinopathy (Diabetic Retinopathy Clinical Research Network /NIH)

Co-investigator, 2010-

DRCRnet Protocol O. Comparison of time-domain OCT and spectral domain OCT retinal thickness measurement in diabetic macular edema (Diabetic Retinopathy Clinical Research Network /NIH)

Co-investigator, 2009-

Age-Related Eye Disease Study 2 (National Eye Institute/ NIH)

Co-investigator, 2006-

DRCRnet Protocol H. A Phase 2 evaluation of anti-VEGF therapy for diabetic macular edema: bevacizumab (Avastin) (Diabetic Retinopathy Clinical Research Network /NIH)

Co-investigator, 2006-2008

DRCRnet Protocol E. A pilot study of peribulbar triamcinolone acetonide for diabetic macular edema (Diabetic Retinopathy Clinical Research Network /NIH)

Co-investigator, 2005-2007

Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study (National Eye Institute/ NIH)

Co-investigator, 2005-2007

DRCRnet Protocol B. A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema (Diabetic Retinopathy Clinical Research Network /NIH)

Co-investigator, 2004-2007

Diabetic Retinopathy Clinical Research Network (DRCRnet) Protocol #1A. A pilot study of laser photocoagulation for diabetic macular edema (Diabetic Retinopathy Clinical Research Network /NIH)

Co-investigator, 2003-2007

Family Investigation of Nephropathy and Diabetes – FIND (National Institute of Diabetes and Digestive and Kidney Diseases/NIH)

Co-investigator/Study Ophthalmologist. 2000-

Epidemiology of Diabetes Interventions and Complications Trial – EDIC (National Institute of Diabetes and Digestive and Kidney Diseases/NIH)

Co-investigator, 1998-

Complications of Age-related Macular Degeneration Prevention Trial – Laser treatment of drusen – CAPT (National Eye Institute/ NIH)

Co-investigator, 1998-2007

Other National Clinical Trials

A randomized, placebo controlled, double-masked, multicenter trial of microplasmin intravitreal injection for non-surgical treatment of focal vitreomacular adhesion (ThromboGenics)

Principal investigator, 2008-2010

A multicenter, randomized, placebo-controlled, double-masked, parallel group, dose-ranging clinical trial of intravitreal microplasmin in patients undergoing surgical vitrectomy: The MIVI III (Microplasmin for Vitreous Injection III) Trial (ThromboGenics)

Principal investigator, 2007-2009

COBALT: COmbining Bevasiranib And Lucentis Therapy. A phase III, randomized, double-masked, parallel-assignment study of intravitreal bevasiranib sodium, administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis®, compared with Lucentis® monotherapy every 4 weeks in patients with exudative age-related macular degeneration (AMD) (Opko)

Principal investigator, 2007-2008

FVF3689g (SAILOR): A Phase IIIb, multicenter study to evaluate the safety and tolerability of ranibizumab in naïve and previously treated subjects with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) (Genentech)

Principal investigator, 2006-2007

Protocol FVF3426g (HORIZON): An open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with subfoveal choroidal

neovascularization (CNV) secondary to age related macular degeneration (AMD) who have completed the treatment phase of a Genentech-sponsored ranibizumab study (Genentech)
Principal investigator, 2006-2007

Cand5 Anti-VEGF RNAi Evaluation (CARE): Dose comparison of Cand5 for subfoveal choroidal neovascularization associated with wet age-related macular degeneration (Acuity Pharmaceuticals)
Principal investigator, 2005-2007

An open label study for the evaluation of tolerability of four dose levels of Cand5 (RNA-interference) administered by single intravitreal injection in patients with wet age-related macular degeneration (Acuity Pharmaceuticals)
Principal investigator, 2005-2007

RNAi Assessment of Cand5 in Diabetic Macular Edema (RACE) (Opko)
Principal investigator, 2005-2007

The effect of ruboxistaurin on clinically significant macular edema in patients with diabetes mellitus, as assessed by optical coherence tomography (Eli Lilly & Company)
Principal investigator, 2005-

A randomized, double-masked, placebo controlled, parallel group, multi-center, dose-ranging study of denifosol tetrasodium (INS37217) intravitreal injection in subjects with rhegmatogenous retinal detachment (Inspire Pharmaceuticals)
Principal investigator, 2004-2005

Protocol FVF2587g: a Phase III, multicenter, randomized, double-masked, active treatment-controlled study of the efficacy and safety of rhuFabv2 (ranibizumab) compared with verteporfin (Visudyne®) photodynamic therapy in subjects with predominantly classic neovascular age-related macular degeneration (Genentech)
Principal investigator, 2003-2006

Intravitreal Steroid Injection Studies (ISIS)
Principal investigator, 2002-2006

Dose-ranging study of pazopanib to treat neovascular age-related macular degeneration (GlaxoSmithKline)
Co-investigator, 2010-

Phase 1a, multicenter, open-label, single-dose, dose-escalation study of the safety, tolerability, pharmacokinetics, and immunogenicity of intravitreal injections of FCFD4514S in patients with geographic atrophy (Genentech)
Co-investigator, 2009-2010

Phase III, double-masked, multicenter, randomized, active treatment-controlled study of the efficacy and safety of 0.5 mg and 2.0 mg ranibizumab administered monthly or on an as-needed basis (PRN) in patients with subfoveal neovascular age-related macular degeneration (HARBOR) (Genentech)

Co-investigator, 2009-

Geographic Atrophy Treatment Evaluation (GATE) Study (Alcon)

Co-investigator, 2009-

Impact of Lucentis on psychological morbidity in patients with macular edema and neovascularization secondary to retinal vein occlusion

Co-investigator, 2009-

Randomized, double-masked, placebo-controlled, add-on study to assess the efficacy of oral aliskiren 300 mg once daily for diabetic macular edema (Novartis)

Co-investigator, 2009-2010

Natural History of Geographic Atrophy Progression (GAP) Study (Alcon)

Co-investigator, 2008-2009

Phase 2, randomized, double-masked, placebo-controlled, dose-ranging clinical study to assess the safety and efficacy of subconjunctival injections of sirolimus in patients with diabetic macular edema secondary to diabetic retinopathy (MacuSight)

Co-investigator, 2008-2010

Phase 1, single ascending dose and parallel group trial to establish the safety, tolerability, and pharmacokinetic profile of multiple intravitreal injections of Volociximab ($\alpha 5\beta 1$ integrin antagonist) as monotherapy or given in combination with Lucentis 0.5mg/eye in subjects with neovascular AMD (Ophthotech 3000)

Co-investigator, 2008-

Anecortave acetate for treatment of steroid-induced intraocular pressure (IOP) elevation (Alcon)

Co-investigator, 2008-2009

Phase 1, single ascending dose trial to establish the safety, tolerability, and pharmacokinetic profile of intravitreal injections of E10030 (anti-PDGF pegylated aptamer) monotherapy and of E10030 given in combination with Lucentis 0.3mg/eye in subjects with neovascular AMD (Ophthotech 1000)

Co-investigator, 2007-

A masked, multicenter, randomized, controlled trial to assess the safety and efficacy of 700 μ g dexamethasone posterior segment drug delivery system (DEX PS DDS) applicator system in combination with laser photocoagulation compared with laser photocoagulation alone in the treatment of subjects with diffuse diabetic macular edema (Allergan)

Co-investigator, 2007-2008

A study of ranibizumab injection in subjects with clinically significant with macular edema center involvement secondary to diabetes mellitus (RIDE) (Genentech)

Co-investigator, 2007-

Indocyanine green (ICG) angiographic evaluation of ranibizumab (Lucentis®) treatment of pigment epithelial detachment (PED) associated with age-related macular degeneration (AMD)

Co-investigator, 2007-2009

OMEGA: A randomized, double-masked, dose-ranging, multi-center, phase II study comparing the safety and efficacy of OT-551 with placebo to treat geographic atrophy associated with age-related macular degeneration (Othera)

Co-investigator, 2007-2008

Denali: a 24-month randomized, double-masked, controlled, multicenter, phase IIIB study assessing safety and efficacy of verteporfin (Visudyne®) photodynamic therapy administered in conjunction with ranibizumab (Lucentis®) versus ranibizumab (Lucentis®) monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (Novartis)

Co-investigator, 2007-2008

Phase II randomized, double-masked, placebo-controlled, dose-comparison study of the safety and efficacy of fenretinide in the treatment of geographic atrophy in age-related macular degeneration (Sirion Therapeutics)

Co-investigator, 2007-2010

Age-related Macular Degeneration: Detection of Onset of new Choroidal neovascularization (AMD DOC) study comparing preferential hyperacuity perimetry (PHP) with supervised Amsler grid in detecting AMD for earlier treatment in high-risk fellow eyes (Johns Hopkins)

Co-investigator, 2007-2009

Phase IV, open label, multicenter trial of maintenance intravitreal injections of Macugen® (pegaptanib sodium) given every 6 weeks for 48 weeks in subjects with subfoveal neovascular age-related macular degeneration (AMD) initially treated with a modality resulting in maculopathy improvement (Eyeteck 1023) ([OSI] Eyeteck)

Co-investigator, 2006-2008

Efficacy and safety of intravitreal injection of Macugen for recent onset neovascular lesions of AMD (Pfizer)

Co-investigator, 2006-2008

Phase III, multicenter, masked, randomized, sham controlled trial to assess the safety and efficacy of DEX PS DDS (700 micrograms, 350 micrograms, or placebo) in the treatment of patients with diabetic macular edema (Allergan)

Co-investigator, 2006-2008

Macugen (pegaptanib sodium) for angioid streaks complicated by choroidal neovascular membrane

Co-investigator, 2006-2010

Macugen (pegaptanib sodium) for pathological myopia complicated by subfoveal choroidal neovascularization

Co-investigator, 2006-2010

Phase III, multicenter, masked, randomized, sham controlled trial to assess the safety and efficacy of DEX PS DDS (700 micrograms, 350 micrograms, or placebo) in the treatment of patients with macular edema following central retinal vein occlusion or branch retinal vein occlusion (Allergan)

Co-investigator, 2005-2008

Protocol OT-551-002: a multi-center, double-masked, randomized, vehicle-controlled, parallel group evaluation of the safety and efficacy of OT-551 ophthalmic solution to prevent formation or delay progression of nuclear cataract formation in post-vitreectomy patients (Othera)

Co-investigator, 2005-2007

Ocular side effects of Cialis vs. Viagra vs. placebo (Eli Lilly & Company)

Co-investigator, 2005-2006

Natural and family history studies of macular telangiectasia (MacTel Foundation)

Co-investigator, 2005-

Interval Dose Evaluation of Anecortave Acetate (IDEAA) Study (Alcon)

Co-investigator, 2005-2008

Phase II, dose ranging, open-labeled, multi-center study to evaluate the safety and efficacy of combretastatin A4 phosphate for treating subfoveal choroidal neovascularization in subjects with pathologic myopia (OXiGENE)

Co-investigator, 2005-2006

A 24-month randomized, double-masked, sham controlled, multicenter, phase IIIB study comparing photodynamic therapy with verteporfin (Visudyne[®]) plus two different dose regimens of intravitreal triamcinolone acetonide (1 mg and 4 mg) versus Visudyne[®] plus intravitreal pegaptanib (Macugen[®]) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (Novartis)

Co-investigator, 2005-2006

Phase 4, randomized, active controlled, double-masked, single dummy, to compare the safety and efficacy of Macugen every 6 weeks plus sham PDT to Macugen every 6 weeks with PDT in patients with predominantly classic CNV (Eyeteck 1012) (Eyeteck Pharmaceuticals)

Co-investigator, 2005-2006

A Phase II randomized, double-masked, safety, efficacy, and pharmacokinetics study of Macugen vs. placebo given every 6 weeks for 30 weeks for vision loss due to macular edema secondary to CRVO (Eyeteck 1011) (Eyeteck Pharmaceuticals)

Co-investigator, 2004-2006

A Phase II prospective, randomized, double-masked, sham controlled, dose-ranging, multi-center trial to assess the effect of pegaptanib sodium on fovea thickening in patients with exudative subfoveal age-related macular degeneration (EyeTech 1009) (Eyetechnical Pharmaceuticals)

Co-investigator, 2005-2007

A Phase I/2, randomized, masked, single and multiple-dose, sequential dose-escalation study of the safety and efficacy of AG-013958 in subjects with subfoveal choroidal neovascularization associated with age-related macular degeneration (Pfizer)

Co-investigator, 2004-2006

Anecortave Acetate Risk-Reduction Trial (Alcon Laboratories)

Co-investigator, 2004-2008

Protein Kinase C β Inhibitor Study B7A-MC-MBDL. Reduction in the occurrence of center-threatening diabetic macular edema (Eli Lilly & Company)

Co-investigator, 2004-2010

Multicenter, open label, flexible-dose, parallel-group evaluation of the cataractogenic potential of quetiapine fumarate (Seroquel™) and risperidone (Risperdal™) in the long term treatment of patients with schizophrenia or schizoaffective disorder

Co-investigator/Evaluating ophthalmologist, 2003-2008

Visudyne Patient Registry

Co-investigator, 2003-2007

The Implantable Miniature Telescope (IMT™) in patients with central vision impairment associated with age-related macular degeneration or Stargardt's macular dystrophy (VisionCare Ophthalmic Technologies)

Co-investigator, 2003-2005

A randomized, double-masked, multi-center trial of the safety, tolerability and pharmacokinetics of 1 mg/eye and 3 mg/eye intravitreal injections of pegaptanib sodium (anti-VEGF pegylated aptamer) given every 6 weeks for 54 weeks, in patients with exudative age-related macular degeneration (EyeTech 1006) (EyeTech Pharmaceuticals)

Co-investigator, 2002-2006

A Phase II randomized, controlled, double-masked, dose-finding, multi-center, comparative trial, in parallel groups, to establish the safety and preliminary efficacy of intravitreal injections of EYE001 (anti-VEGF pegylated aptamer), given every 6 weeks for 12 to 30 weeks to patients with clinically significant diabetic macular edema (CSME) involving the center of the macula (EyeTech 1005) (EyeTech Pharmaceuticals)

Co-investigator, 2002-2003

Oculex Study: A phase 2 randomized, multicenter, dose-ranging, controlled, parallel-group trial to assess the safety and effectiveness of dexamethasone posterior segment drug delivery system (DEX PS DDS[®]) in the treatment of persistent macular edema (Oculex Pharmaceuticals)

Co-investigator, 2001-2003

Fluocinolone Acetonide in Diabetic Macular Edema (FAME 4) Study: A multicenter, randomized, masked, controlled study to evaluate the safety and efficacy of Retisert[™], an intravitreal fluocinolone acetonide implant, in the treatment of patients with diabetic macular edema (Bausch & Lomb)

Co-investigator, 2001-2007

Visudyne[™] Early Retreatment (VER) Study: Multicenter, randomized, parallel group, double-masked, controlled phase IIIb, 2-year study comparing the efficacy and safety of Visudyne[™] therapy with early retreatment to standard treatment in predominantly classic subfoveal choroidal neovascularization secondary to age-related macular degeneration (Novartis Ophthalmics/CIBA)

Co-investigator, 2001-2003

Phase II/III randomized, double-masked, controlled, dose-ranging, multicenter comparative trial, in parallel groups, to establish the safety and efficacy of intravitreal injections of EYE001 (anti-VEGF pegylated aptamer) given every 6 weeks for 54 weeks in patients with age-related macular degeneration (EyeTech 1004) (EyeTech Pharmaceuticals)

Co-investigator, 2001-2005

Transpupillary thermotherapy for the treatment of subfoveal occult choroidal neovascular membranes in patients with age-related macular degeneration (Iridex)

Co-investigator, 2000-2004

Verteporfin in Age-related Macular degeneration (VAM) Study: Open-label, multicenter, safety study of the treatment of predominantly classic choroidal neovascularization secondary to age-related macular degeneration using photodynamic therapy with verteporfin for injection (Novartis Ophthalmics/CIBA)

Co-investigator, 1999-2000

Evaluation of safety and duration of efficacy of anecortave acetate sterile suspension versus placebo following a single sub-Tenon's injection for the inhibition of neovascularization in patients with exudative age-related macular degeneration (Alcon Laboratories)

Co-investigator, 1998-2001

Verteporfin in Photodynamic Therapy Study (Novartis Ophthalmics/CIBA)

Co-investigator, 1998-2003

Protein kinase C β inhibitor studies: Diabetic Macular Edema Study and Diabetic Retinopathy Study. (Eli Lilly & Company)

Co-investigator, 1998-2002

Metalloprotease inhibitor for subfoveal choroidal neovascular membranes in patients with macular degeneration (Agouron Pharmaceuticals)
Co-investigator, 1998-2001

SELECTED PRESENTATIONS AT LOCAL, NATIONAL, AND INTERNATIONAL MEETINGS AND SYMPOSIA

1. Unresponsive wet AMD. North Coast Retina Symposium. Cole Eye Institute, Cleveland Clinic Foundation. Cleveland, Ohio. May 13, 2011.
2. Chemical vitrectomy. Optometric Retinal Update Seminar. Beachwood, Ohio. March 3, 2011.
3. Recent developments in the etiology, treatment, and research of age-related macular degeneration. Cleveland Eye Clinic Update on Macular Degeneration, OCT Imaging, and Retinal Disease. Cleveland, Ohio. January 26, 2011.
4. Chemical vitrectomy. Cleveland Ophthalmological Society. Cleveland, Ohio. October 12, 2010.
5. Neovascular glaucoma. Optometric Retinal Update Seminar. Westlake, Ohio. August 19, 2010.
6. Surgery for neovascular glaucoma: two birds with one stone? American Eye Study Club Annual Meeting. Nemacon Woodland Resort; Farmington, Pennsylvania. August 3-7, 2010.
7. Singerman LJ, Novak MA, Miller DG, Coney JC, et al. Ranibizumab treatment for pigment epithelial detachment (PED) in age-related macular degeneration (AMD). Retina Congress 2009, Combined Meeting of the American Society of Retina Specialists, The Macula Society, and The Retina Society. New York, New York. September 30-October 4, 2009.
8. Coney JM. Retina surgery videos (with David G. Miller, MD). National Medical Association Annual Meeting. Las Vegas, Nevada. July 25-29, 2009.
9. Chemical vitrectomy: clinical trial of intravitreal microplasmin. American Eye Study Club. Colorado Springs, Colorado. July 23, 2009.
10. Participant, Practice Management Symposium. American Eye Study Club. Colorado Springs, Colorado. July 24, 2009.
11. Interesting retinal cases. Northeast Ohio Vision Source meeting. Ashland, Ohio. July 8, 2009.
12. Chemical vitrectomy: clinical trial of intravitreal microplasmin. Optometric Retinal Update Seminar. June 18, 2009.

13. Berlon NR, Miller DG, Novak MA, Pendergast SD, Coney JC. Safety and efficacy of 25-gauge vitrectomy surgery by experienced vitreoretinal surgeons. Association for Research in Vision and Ophthalmology Annual Meeting. Program # 5202. Fort Lauderdale, Florida. May 7, 2009.
14. Retinal imaging (with H. Zegarra). Optometric Continuing Education Program and Open House. Lorain, Ohio. January 13, 2009.
15. Surgical techniques for epiretinal membrane removal. Retinal Update for Ophthalmologists. Cleveland, Ohio. November 20, 2008.
16. Small-gauge vitrectomy in our practice: expanded indications. Optometric Retinal Update Seminar. Westlake, Ohio. July 15, 2008
17. Small-gauge vitrectomy in our practice: expanded indications. 8th Congress of the Croatian Ophthalmological Society. Sibenik, Croatia. May 8-10, 2008.
18. 25-gauge surgery for macular hole repair. American Eye Study Club, 50th Annual Meeting. Ritz Carlton Bachelor Gulch, Beaver Creek, Colorado. July 22-26, 2007.
19. Update on diabetic retinopathy: diagnosis and treatment. Optometric Retinal Update Seminar. Westlake, Ohio. July 17, 2007.
20. Macular hole repair. Optometric Retinal Update Seminar. Beachwood, Ohio. February 15, 2007.
21. Results of surgical management of senile macular holes by 25-gauge trans-conjunctival sutureless vitrectomy compared to standard vitrectomy systems. Annual meeting of the American Society of Retina Specialists. Cannes, France. September 8-13, 2006.
22. Treating macular degeneration with ranibizumab (Lucentis). Optometric Retinal Update Seminar. Westlake, Ohio. August 10, 2006.
23. Vitrectomy surgery. Parma Community General Hospital Retinal Update. Parma, Ohio. March 21, 2006.
24. Angiography in macular degeneration: Avastin and Lucentis. Optometric Retinal Update Seminar. Beachwood, Ohio. February 9, 2006.
25. Pharmacotherapy for age-related macular degeneration. Michigan Ophthalmological Society. Detroit, Michigan. November 16, 2005.
26. Update on treatments for age-related macular degeneration. Buffalo Eye Club. Buffalo, New York. October 27, 2005.
27. Modern retinal imaging. Optometric Retinal Update Seminar. Westlake, Ohio. August 11, 2005

28. Flashes & floaters. Optometric Retinal Update Seminar. Beachwood, Ohio. February 15, 2005
29. Cataract surgery and retinal disease. Optometric Retinal Update Seminar. Westlake, Ohio. July 29, 2004.
30. Retinal detachment: principles and treatment. Ohio Ophthalmological Society Annual Meeting. March 20, 2004.
31. Cataract surgery and macular disease. Ohio Ophthalmological Society Annual Meeting. March 20, 2004.
32. Photodynamic therapy and macular degeneration. Optometric Continuing Medical Education. Vermilion, Ohio. December 2003.
33. Retinal complications of toxoplasmosis retinitis. Cleveland Ophthalmological Society. Cleveland, Ohio. October 2003
34. Update on diabetic retinopathy. East-West Eye Conference. Cleveland, Ohio. October 2003.
35. Cataract surgery and retinal diseases. Cleveland Ophthalmological Society. Cleveland, Ohio. October 2003.
36. Pharmacotherapy of treatment of diabetic retinopathy. Optometric Retinal Update Seminar. Westlake, Ohio. August 12, 2003.
37. Implantable miniature telescope. Optometric Retinal Update Seminar. Beachwood, Ohio. February 20, 2003.
38. Update on macular degeneration. Cuyahoga Community College Encore Campus. Cleveland, Ohio. November 1, 2002.
39. Posterior segment complications and other challenges of LASIK in the high myope (with Mohinder K. Gupta, MD, co-instructor). American Society of Cataract and Refractive Surgery. Philadelphia, Pennsylvania. June 4, 2002.
40. Intravitreal triamcinolone acetonide for the treatment of macular edema. Cleveland Ophthalmological Society. Cleveland, Ohio. February 12, 2002.
41. The future of retinal care. Ohio Optometric Society. The Symposium of the Future. Cleveland, Ohio. February 4, 2002.
42. The myopic retina. Optometric Refractive Surgery Society, 6th Annual Symposium; August 2001. 1) Update on Diabetic Retinopathy; 2) Update on Age-related Macular Degeneration; and 3) Retinal Complications of High Myopia. Society for Excellence in Eyecare Conference; Aruba. January 27-31, 2002.

43. Update on photodynamic therapy with Visudyne. State University of New York, Visiting Professor. May 2001.
44. Unusual presentation of posterior scleritis. Cleveland Ophthalmological Society. Cleveland, Ohio. 2001.
45. Controversy in the management of posterior segment trauma. Cleveland Ophthalmological Society. Cleveland, Ohio. 2000.
46. Surgical management of macular hole. East-West Eye Conference. Cleveland, Ohio. 1999.
47. What's new in macula. East-West Eye Conference; Cleveland, Ohio, 1999.
48. Update on the management of age-related macular degeneration. East-West Eye Conference. Cleveland, Ohio. 1999.
49. Treatment of macular hole. Massachusetts Eye and Ear Infirmary Seminar, Surgical Advances in Ophthalmology. 1998.
50. Presumed ocular histoplasmosis syndrome and corticosteroids. Indiana University. 1997.
51. The use of corticosteroids in the treatment of histoplasmosis-related subfoveal choroidal neovascularization. Association for Research and Vision in Ophthalmology Annual Meeting. Fort Lauderdale, Florida, 1997.
52. Patient satisfaction with orbicectomy in the treatment of blepharospasm. Indiana University, 1996.

PUBLICATIONS

Journal Articles

1. O'Grady MJ, Bressler NM, Glassman AR for the Diabetic Retinopathy Clinical Research Network. Economic analysis of ranibizumab treatment of diabetic macular edema. *JAMA* (submitted 2011).
2. Schartman JP, Coney JM, Miller DG. Pegaptanib octasodium for the treatment of diabetic macular oedema. *Expert Opinion on Pharmacotherapy* 2011;12:1317-1323.
3. Diabetic Retinopathy Clinical Research Network; Writing Committee, Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL 3rd, Friedman SM, Glassman AR, Scott IU, Stockdale CR, Sun JK. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. *Ophthalmology* 2011;118:609-614.
4. Flaxel CJ, Edwards AR, Aiello LP, Arrigg PG, Beck RW, Bressler NM, Bressler SB, Ferris FL 3rd, Gupta SK, Haller JA, Lazarus HS, Qin H. Factors associated with visual

- acuity outcomes after vitrectomy for diabetic macular edema: Diabetic Retinopathy Clinical Research Network. *Retina* 2010;30:1488-1495.
5. Danis RP, Scott IU, Qin H, Altaweel MM, Bressler NM, Bressler SB, Browning DJ, Kollman C; For The Diabetic Retinopathy Clinical Research Network. Association of fluorescein angiographic features with visual acuity and with optical coherence tomographic and stereoscopic color fundus photographic features of diabetic macular edema in a randomized clinical trial. *Retina*. 2010 Aug 12. [Epub ahead of print]
 6. Ferris FL 3rd, Miller KM, Glassman AR, Beck RW; Diabetic Retinopathy Clinical Research Network. A proposed method of logarithmic transformation of optical coherence tomography data for use in clinical research. *Ophthalmology* 2010;117:1512–1516.
 7. Diabetic Retinopathy Clinical Research Network Writing Committee on behalf of the DRCR.net. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. *Ophthalmology* 2010;117:1087-1093.
 8. Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. *Ophthalmology* 2010;117:1064-1077.
 9. Aiello LP, Edwards AR, Beck RW, Bressler NM, Davis MD, Ferris F, Glassman AR, Ip MS, Miller KM; Diabetic Retinopathy Clinical Research Network. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. *Ophthalmology*. 2010;117:946-953.
 10. Coney JM, Miller DG. Epiretinal membrane. *Focal Points*. Volume XXVII, Number 5, American Academy of Ophthalmology, 2009.
 11. Bhavsar AR, Googe JM Jr, Stockdale CR, Bressler NM, Brucker AJ, Elman MJ, Glassman AR; Diabetic Retinopathy Clinical Research Network. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials. *Arch Ophthalmol* 2009;127:1581-1583.
 12. Bressler NM, Edwards AR, Beck RW, Flaxel CJ, Glassman AR, Ip MS, Kollman C, Kuppermann BD, Stone TW; Diabetic Retinopathy Clinical Research Network. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetate with focal/grid photocoagulation. *Arch Ophthalmol* 2009;127:1566-1571.
 13. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. *Arch Ophthalmol* 2009;127:1115-1128.

14. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. *Arch Ophthalmol* 2009;127:1101-1114.
15. Diabetic Retinopathy Clinical Research Network. The course of response to focal/grid photocoagulation for diabetic macular edema. *Retina* 2009 Nov-Dec;29:1436-1443.
16. Scott IU, Danis RP, Bressler SB, Bressler NM, Browning DJ, Qin H; Diabetic Retinopathy Clinical Research Network. Effect of focal/grid photocoagulation on visual acuity and retinal thickening in eyes with non-center-involved diabetic macular edema. *Retina* 2009 May;29:613-617.
17. Browning DJ, Apte RS, Bressler SB, Chalam KV, Danis RP, Davis MD, Kollman C, Qin H, Sadda S, Scott IU; Diabetic Retinopathy Clinical Research Network. Association of the extent of diabetic macular edema as assessed by optical coherence tomography with visual acuity and retinal outcome variables. *Retina* 2009 Mar;29:300-305.
18. Ip MS, Oden NL, Scott IU, VanVeldhuisen PC, Blodi BA, Figueroa M, Antoszyk A, Elman M and the SCORE Study Investigator Group. SCORE Study Report 3: Study design and baseline characteristics. *Ophthalmology* 2009;116:1770-1777.
19. Diabetic Retinopathy Clinical Research Network (DRCR.net), Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, Hartnett E, Ip MS, Kim JE, Kollman C. Three-year follow up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. *Arch Ophthalmol* 2009;127:245-251.
20. Diabetic Retinopathy Clinical Research Network, Brucker AJ, Qin H, Antoszyk AN, Beck RW, Bressler NM, Browning DJ, Elman MJ, Glassman AR, Gross JG, Kollman C, Wells JA 3rd. Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. *Arch Ophthalmol* 2009;127:132-140.
21. Sun JK, Aiello LP, Stockman M, Cavallerano JD, Kopple A, Eagan S, Qin H, Kollman C, Beck RW, Glassman AR; Diabetic Retinopathy Clinical Research Network. Effects of dilation on Electronic-ETDRS Visual Acuity in diabetic patients. *Invest Ophthalmol Vis Sci* 2009;50:1580-1584.
22. Glassman AR, Beck RW, Browning DJ, Danis RP, Kollman C; Diabetic Retinopathy Clinical Research Network Study Group. Comparison of optical coherence tomography in diabetic macular edema, with and without reading center manual grading from a clinical trials perspective. *Invest Ophthalmol Vis Sci* 2009;50:560-566
23. Complications of Age-related Macular Degeneration Prevention Trial (CAPT) Research Group. Risk factors for choroidal neovascularization and geographic atrophy in the

- complications of age-related macular degeneration prevention trial. *Ophthalmology* 2008;115:1474-1479, 1479.e1-6. Epub 2008 May 27.
24. Maguire MG, Alexander J, Fine SL; Complications of Age-related Macular Degeneration Prevention Trial (CAPT) Research Group. Characteristics of choroidal neovascularization in the complications of age-related macular degeneration prevention trial. *Ophthalmology* 2008;115:1468-1473, 1473.e1-2. Epub 2008 May 16.
 25. Ip MS, Bressler SB, Antoszyk AN, Flaxel CJ, Kim JE, Friedman SM, Qin H, Jaeb Center for Health Research and the Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone and laser photocoagulation for diabetic macular edema: baseline features. *Retina* 2008;.28:919-930.
 26. Davis MD, Bressler SB, Aiello LP, Bressler NM, Browning DJ, Flaxel CJ, Fong DS, Foster WJ, Glassman AR, Hartnett MER, Kollman C, Li HK, Qin Q, Scott IU; the Diabetic Retinopathy Clinical Research Network Study Group. Comparison of time-domain OCT and fundus photographic assessments of retinal thickening in eyes with diabetic macular edema. *Invest Ophthalmol Vis Sci* 2008;49:1745-1752.
 27. Ying G-S, Maguire M, Liu C, Antoszyk A, Complications of Age-related Macular Degeneration Prevention Trial Research Group. Night vision symptoms and progression of age-related macular degeneration (AMD) in the Complications of AMD Prevention Trial. *Ophthalmology*. Epub 2008 Jul 30.
 28. Bressler NM, Edwards AR, Antoszyk AN, Beck RW, Browning DJ, Ciardella AP, Danis RP, Elman MJ, Friedman SM, Glassman AR, Gross JG, Li HK, Murtha TJ, Stone TW, Sun JK; Diabetic Retinopathy Clinical Research Network. Retinal thickness on Stratus optical coherence tomography in people with diabetes and minimal or no diabetic retinopathy. *Am J Ophthalmol* 2008;145:894-901.
 29. Browning DJ, Altaweel MM, Bressler NM, Bressler SB, Scott IU; Diabetic Retinopathy Clinical Research Network. Diabetic macular edema: what is focal and what is diffuse? *Am J Ophthalmol* 2008;146:649-655.e1-6.
 30. Clemons TE, Gillies MC, Chew EY, Bird AC, Peto T, Figueroa M, Harrington MW; Macular Telangiectasia Research Group. The National Eye Institute Visual Function Questionnaire in the Macular Telangiectasia (MacTel) Project. *Invest Ophthalmol Vis Sci* 2008;49:4340-4346.
 31. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. *Ophthalmology* 2008;115:1447-1449, 1449.e1-10. Epub 2008 Jul 26.
 32. Browning DJ, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, Davis MD, Ferris FL, Huang SS, Kaiser PK, Kollman C, Sadda S, Scott IU, Qin H; Diabetic Retinopathy Clinical Research Network. Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. *Ophthalmology* 2008;115:1366-71, 1371.e1.

33. ISIS-DME: a prospective, randomized, dose-escalation intravitreal steroid injection study for refractory diabetic macular edema. Kim JE, Pollack JS, Miller DG, Mitra RA, Spaide RF; ISIS Study Group. *Retina* 2008 May;28(5):735-40.
34. Scott IU, Bressler NM, Bressler SB, Browning DJ, Chan CK, Danis RP, Davis MD, Kollman C, Qin H; Diabetic Retinopathy Clinical Research Network Study Group. Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema. *Retina* 2008;28:36-40.
35. Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, Friedman SM, Greven CM, Maturi RK, Pieramici DJ, Shami M, Singerman LJ, Stockdale CR. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. *Ophthalmology* 2007;114:1860-1867.
36. Macugen AMD Study Group, Apte RS, Modi M, Masonson H, Patel M, Whitfield L, Diabetic Retinopathy Clinical Research Network. Randomized trial of peribulbar triamcinolone acetate with and without focal photocoagulation for mild diabetic macular edema: a pilot study. *Ophthalmology* 2007;114:1190-1196.
37. Adamis AP. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. *Ophthalmology* 2007;114:1702-1712.
38. Bhavsar AR, Ip MS, Glassman AR; DRCRnet and the SCORE Study Groups. The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. *Am J Ophthalmol* 2007;144:454-456.
39. Diabetic Retinopathy Clinical Research Network. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. *Ophthalmology* 2007;114:525-536.
40. Diabetic Retinopathy Clinical Research Network. Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. *Ophthalmology* 2007; 114:520-525.
41. Diabetic Retinopathy Clinical Research Network. Comparison of the modified early treatment diabetic retinopathy study and mild macular grid laser photocoagulation strategies for diabetic macular edema. *Arch Ophthalmol* 2007;125:469-480.
42. Russell SR, Hudson HL, Jerdan JA; Anecortave Acetate Clinical Study Group. Anecortave acetate for the treatment of exudative age-related macular degeneration--a review of clinical outcomes. *Surv Ophthalmol* 2007;52 Suppl 1:S79-90.
43. Miller DG, Singerman LJ. Vision loss in younger patients: a review of choroidal neovascularization. *Optom Vis Sci*;83:316-325, 2006.

44. Diabetic Retinopathy Clinical Research Network, Danis RP, Glassman AR, Aiello LP, Antoszyk AN, Beck RW, Browning DJ, Ciardella AP, Kinyoun JL, Murtha TJ, Topping TM, Shami M, Sharuk GS, Wells JA 3rd. Diurnal variation in retinal thickening measurement by optical coherence tomography in center-involved diabetic macular edema. *Arch Ophthalmol* 2006;124:1701-1707.
45. Complications of Age-related Macular Degeneration Prevention Trial Research Group. Laser treatment in patients with bilateral large drusen: The Complications of Age-Related Macular Degeneration Prevention Trial. *Ophthalmology* 113:1974-1986, 2006.
46. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, Chakravarthy U, Adamis AP, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, Patel M. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. *Ophthalmology* 2006;113:1508-1521.
47. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET Jr, Guyer DR, Katz B. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. *Ophthalmology* 2006;113:992-1001.
48. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. *N Engl J Med* 355:1432-1444, 2006.
49. Gonzales CR; VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. *Retina* 2005;25:815-827.
50. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. *N Engl J Med* Dec 30;351:2805-2816, 2004.
51. Maguire M; Complications of Age-Related Macular Degeneration Prevention Trial Research Group. Baseline characteristics, the 25-Item National Eye Institute Visual Functioning Questionnaire, and their associations in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT). *Ophthalmology* 111:1307-1316, 2004.
52. Complications of Age-related Macular Degeneration Prevention Trial Study Group. The Complications of Age-related Macular Degeneration Prevention Trial (CAPT): rationale, design, and methodology. *Clinical Trials* 1:91-107, 2004.

53. Azab M, Benchaboune M, Blinder KJ, et al; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group; Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment of Age-Related Macular Degeneration with Photodynamic Therapy and Verteporfin in Photodynamic Therapy Study Report no. 4. *Retina* 2004;24:1-12.
54. Singerman LJ, Miller DG. Pharmacological treatments for AMD. *Rev Ophthalmol* 10: 88-90, 92, 94; 2003. http://www.revophth.com/index.asp?page=1_422.htm
55. D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger DS, Luna SP, Robertson SM, Russell S, Singerman L, Slakter JS, Yannuzzi L, Zilliox P; Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. *Ophthalmology* 110:2372-2383, 2003.
56. D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger S, Luna S, Robertson SM, Russell S, Singerman L, Slakter JS, Sullivan EK, Yannuzzi L, Zilliox P; The Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. *Retina* 23:14-23, 2003.
57. The Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration. Phase II study results. *Ophthalmology* 110:979-986, 2003.
58. Singerman LJ, Miller DG. Diabetic retinopathy and DME drug trials advance. *Rev Ophthalmol* 10:124-127, 2002. http://www.revophth.com/index.asp?page=1_204.htm
59. Miller DG, Singerman LJ. The natural history of choroidal neovascularization in high myopia. *Current Opinion in Ophthalmology* 12:222-224, 2001.
60. Martidis A, Miller DG, Ciulla RP, Moorthy RS. Corticosteroids as an antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascularization. *Journal of Ocular Pharmacology and Therapeutics* 15:425-428, 1999.
61. Miller DG, Lou PL, Kroll AJ, Ryan EA. Surgical management of macular hole. *International Ophthalmology Clinics* 39:261-274, Winter 1999.
62. Miller DG, Ryan EA. Removal of silicone oil. [Letter] *VitreoTech*, Volume 3, June 1998.
63. Miller DG, Evans R, Blaustein A. Does hydrogen peroxide mediate changes in stunned myocardium? *Clinical Research*, Volume 39, April 1991.

Book Chapters

1. Miller DG, Sharma MC, Singerman LJ. Laser treatment of age-related macular degeneration. In Boyd BF, Boyd S (eds.). *Retinal and Vitreoretinal Surgery: Mastering the Latest Techniques*. Panama: Highlights of Ophthalmology Press, 2005, pp. 250-261.
2. Miller DG, Singerman LJ. Key questions for a focused history. In Steidl SM, Hartnett ME (eds.). *Clinical Pathways in Vitreoretinal Disease*. New York: Thieme, 2003, pp 3-12.
3. Miller DG, Singerman LJ. Laser treatment of age-related macular degeneration. In Boyd BF, Boyd S (eds.). *Retinal and Vitreoretinal Surgery: Mastering the Latest Techniques*. Panama: Highlights of Ophthalmology Press, 2002, pp 249-261.
4. Miller DG, Singerman LJ. Diabetic retinopathy: medical considerations. In Saer JB (ed.). *Vitreo-Retinal and Uveitis Update. Proceedings of the New Orleans Academy of Ophthalmology Symposium*. The Hague: Kugler Publications, 1998, pp 239-244.

Abstracts

1. Brown CC, Miller DG. Results of surgical management of senile macular holes by 25-gauge trans-conjunctival sutureless vitrectomy. *American Society of Retina Specialists Meeting Abstracts*; 2006; <http://www.asrs.org/meetings/abstracts/2006/>.
2. Federman JL, Martidis A, Nelson ML, Belmont JB, Sivalingam A, Miller DG. Intravitreal triamcinolone for refractory diabetic macular edema. *Macula Society Meeting Abstracts*, 2002, p 32.
3. Nelson ML, Martidis A, Miller DG, Spinak DJ, Federman JL. Intravitreal triamcinolone acetone injection for refractory pseudophakic cystoid macular edema. *Retina Congress 2002 Abstracts*, <http://www.vitreoussociety.org/sf2002/index.html>
4. Blade KA, Martidis A, Nelson ML, Belmont JB, Miller DG, Ansari I, Sivalingam A. Intravitreal triamcinolone injection for the treatment of macular edema secondary to branch retinal vein occlusion. *Retina Congress 2002 Abstracts*, <http://www.vitreoussociety.org/sf2002/index.html>
5. Martidis A, Nelson ML, Baker B, Duker JS, Reichel E, Rogers AH, Federman JL, Sivalingam A, Belmont JB, Miller DG. Intravitreal triamcinolone for refractory diabetic macular edema. *Retina Congress 2002 Abstracts*, <http://www.vitreoussociety.org/sf2002/index.html>

Posters

1. Brown CC, Miller DG. Results of surgical management of senile macular holes by 25-gauge trans-conjunctival sutureless vitrectomy. Scientific Poster 4641/B976, Association for Research in Vision and Ophthalmology Annual Meeting, May 2006.
2. Prenner JL, Thompson JT, Miller DG, Saran BR, Gordon JF, Brucker AJ, Reich SJ. An

open label study for the evaluation of tolerability of five dose levels of intravitreal VEGF siRNA (Cand5) in patients with wet age-related macular degeneration. Scientific Poster 4632, American Academy of Ophthalmology Annual Meeting, October 2005.

3. Sharma MC, Miller DG, Zakov ZN, Pendergast SD, Novak MA, Zegarra H, Singerman LJ. Results of the surgical management of idiopathic epiretinal membrane. Scientific Poster 472, American Academy of Ophthalmology Annual Meeting, October 2005.
4. Spinak DJ, Martidis A, Miller DG. Intravitreal triamcinolone acetonide injection for refractory pseudophakic cystoid macular edema. Scientific Poster 129, American Academy of Ophthalmology Annual Meeting, October 2002.